Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of olaparib in triple negative breast cancer regardless of BRCA1 mutation statusHélène Marijon, Harold Phillip Koeffler|Oncotarget|2021Cited by 19
Abstract B048: NUC-3373 in combination with irinotecan (NUFIRI) or oxaliplatin (NUFOX) and bevacizumab for second-line treatment of patients with advanced colorectal cancer (NuTide:302)Khurum Khan, T.R. Jeffry Evans, David Cosgrove et al.|Molecular Cancer Therapeutics|2023Cited by 1